Shares in ANGLE PLC (AIM:AGL, OTCQX:ANPCY) were up 4% in early trading after a move by the health chief in the UK highlighted the potential of its technology.
It emerged on Friday that lung cancer sufferers will be offered a pioneering blood test that will potentially fast-track them to targeted therapies that can be less harsh than traditional treatments.
A liquid biopsy system will be used that picks up circulating tumour DNA, allowing doctors to better understand the progression or mutation of the disease.
While ANGLE's Parsortix technology isn't the same, it performs a very similar function in that it picks up circulating tumour cells associated with cancers for analysis.
It is the only device of its kind with US regulatory sign-off for use in breast cancer treatment.
Earlier on Friday, ANGLE told investors it was providing the scientific community an update on the utility of its liquid biopsy at the European Breast Cancer Conference (EBCC) taking place in currently in Milan.
At EBCC, ANGLE will present two studies demonstrating the capabilities of its Parsortix system and Portrait+ CTC Staining Kit.
At 8.18 am, the shares were changing hands for 13.75p, up 0.5p.